GVHD remains the major complication of allo-HSCT. Murine models are the primary system used to understand GVHD, and to develop potential therapies. Several factors are critical for GVHD in these models; including histocompatibility, conditioning regimen, and T-cell number. We serendipitously found that environmental factors such as the caging system and bedding also significantly impact the kinetics of GVHD in these models. This is important because such factors may influence the experimental conditions required to cause GVHD and how mice respond to various treatments. Consequently, this is likely to alter interpretation of results between research groups, and the perceived effectiveness of experimental therapies.
1
We combined clinically relevant doses of myeloablative chemotherapy (CY 60 mg/kg on days À3 and À2) and radiation (1000 cGy, split dose on day À1) before administering 1 Â 10 7 BM cells and 1 Â 10 7 splenocytes (SP) to conditioned recipients on the day of transplant (day 0). Recipient mice were then housed in traditional filter top cages (Techniplast) with sawdust bedding in a PC2 facility.
These mice reliably developed lethal GVHD within 7-11 days (n ¼ 60-100 mice per year). Recently, our animal housing was upgraded to micro-environmental comfort, isolation, containment, enrichment (MICE) cages (Australian Animal Care Systems, Dromana, Victoria, Australia) with an enclosed airflow system and absorbent newspaper pellet bedding. Changes in occupational health and safety requirements also obliged us to change the cages daily for 5 days after the last CY injection. Under these conditions control mice developed lethal GVHD between 7 and 25 days, or not at all, prompting us to investigate whether our upgraded animal facility caused the later onset of the disease.
We therefore compared the kinetics of GVHD in mice housed in different cages or with different bedding material. To directly compare the effect of the caging systems, we monitored GVHD in mice housed in either MICE or Techniplast cages with sawdust bedding that was changed only on day À1. Mice housed in filter top cages developed GVHD necessitating killing earlier (mean survival 6.16 ± 0.4 days) than those housed in the MICE system (mean survival 19.17±2.78, Po0.0005) (Figure 1 ), suggesting that the caging system itself could influence the onset of GVHD.
At the same time, we monitored onset of GVHD in mice housed in the MICE system with absorbent newspaper pellet bedding. We found that the time to lethal GVHD was reduced (mean survival 8±3.5 days) compared with the mice housed in the same system with sawdust bedding, demonstrating that that both caging and bedding can influence the onset of GVHD. One possible explanation may be due to the availability of lipopolysaccharide in each system. Lipopolysaccharide traverses the intestinal mucosa in the conditioningdamaged mice, and activates DCs and macrophages, which are key drivers of GVHD. Factors that influence the cleanliness of the environment, such as the negative pressure and ventilated air flow within the MICE cages or the absorbency of the bedding material may alter bacterial colonisation and consequently, the amount of lipopolysaccharide that leaks across the endothelial barrier. This is supported by early experimental studies, where death from GVHD was prevented in recipient mice if they are either gnotobiotic [2] [3] or administered antibiotics to decontaminate the gut, 4 and in clinical studies which reported that a protective environment such as laminar air flow rooms or gut decontamination reduced GVHD. [5] [6] An important consideration of these observations is that the difference in environmental conditions we used is likely to replicate variation in housing conditions across research institutes, possibly explaining why the number of splenocytes required to induce GVHD in murine models differs greatly between and even within published studies. [7] [8] To investigate this, we administered 1 Â 10 7 BM cells in combination with either 5 Â 10 5 , 1Â 10 6 , 1Â 10 7 or 2 Â 10 7 splenocytes in our major histocompatibility-mismatched model. There was a significant increase in survival in mice receiving the lower splenocyte doses of either 1 Â 10 6 splenocytes (mean day of death 15.5 ± 4.8 n ¼ 6) or 5 Â 10 5 splenocytes (mean day of death 19.67 ± 6.6 n ¼ 6) compared with mice receiving 1 Â 10 7 splenocytes (mean day of death 8±2 days n ¼ 6; Figure 2 , Po0.01). There was no difference in survival in cohorts receiving 1 Â 10 7 or 2 Â 10 7 splenocytes, suggesting that GVHD cannot occur faster regardless of the splenocyte dose. Although the correlation between an increase in T-cell number and a decrease in time to GVHD induction is unsurprising, this factor is often inconsistent between research groups, making comparisons of treatment efficacy difficult.
As a case in point, the effectiveness of MSCs at treating GVHD in murine models is remarkably inconsistent.
We and others have shown that MSCs have limited effect on survival, 9 while others have shown they are highly effective. This is confounded by mixed results from clinical reports whereby MSCs resolved steroid-refractory GVHD, 10 but in a recent large-scale phase III clinical trial, the overall response to MSCs of patients with steroid-refractory GVHD was not different to that of patients receiving placebo (35% treated vs 30% in controls, n ¼ 260) (http://www.osiristx. com). Our results suggest that differences in caging conditions in pre-clinical models may inadvertently have a critical role in validation or negation of potential new therapies for treatment of GVHD.
To progress pre-clinical models to clinical trials, it is important to produce consistent and reliable results. In this study we have highlighted the fact that environmental conditions, and consequently the T-cell dose required to induce GVHD, significantly altered the course of the disease. This may affect the outcome of any novel GVHD therapeutics tested in murine transplant models. We propose that it is essential to both consider carefully and report environmental conditions used in murine models of GVHD to improve the ability of researchers to compare data between research groups. Letter to the Editor
